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Background: Infections are a common cause of morbidity and mortality in patients with acute myeloid leukemia
(AML). The evidence for efficacy of antibiotic prophylaxis in reducing the mortality rates and the incidence of
bacterial infections was also reported by a systematic review published by Cochrane in 2012. The objective of our
study was to report the incidence and the etiology of bloodstream infections in patients with AML undergoing
levofloxacin prophylaxis during neutropenic episodes.
Methods: This was a retrospective study of patients with diagnosis of AML during 2001–2007.
Results: A total of 81 patients were included in the study. Two hundred and ninetyone neutropenic episodes were
studied, of which 181 were febrile. Bacteria isolated from blood cultures were mostly Gram-positives during the
induction (80%) and Gram-negatives during the consolidation (72.4%) phases of chemotherapy. Resistance to
ciprofloxacin was found in 78.9% of isolated E. coli and it was higher during consolidation and higher than the
hospital rate. The production of extended spectrum betalactamases (ESBL) in E. coli strains was reported in 12.1%,
below the reported hospital rate during the study period.
Conclusions: Regular microbiology surveillance is needed to better understand the impact of levofloxacin prophylaxis
in neutropenic patients. Our study shows that Gram-positive bacteria are predominant during the induction phase of
chemotherapy and Gram-negatives during the consolidation. The rate of fluoroquinolone resistance in the latter setting,
even higher than the hospital rate, may suggest to reconsider levofloxacin prophylaxis.
Keywords: Acute myeloid leukemia, Neutropenia, Levofloxacin prophylaxis, Febrile neutropenia, Chemotherapy,
InfectionsBackground
Acute myeloid leukemia (AML) is the most common
acute leukemia in adults. Standard treatment is conven-
tionally divided into the induction phase with anthracycline
and cytarabine and consolidation therapy consisting of
cycles of chemotherapy or stem cell transplantation [1,2].
The survival rate is influenced by the prevention and
management of infectious complications. Infections are a
common cause of morbidity and mortality in patients with
AML. The risk-assessment for infections in neutropenic* Correspondence: francescogiuseppe.derosa@unito.it
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reproduction in any medium, provided the orpatients, according to the IDSA guidelines is classically
divided into high risk (prolonged neutropenia, >7 days;
neutrophils count ≤ 100/mm3; substantial concurrent
comorbidity; clinically unstable) and low risk (neutropenia
expected to resolve within 7 days; no active medical co-
morbidity, clinical stability at onset of the febrile episode;
most of them are patients with solid tumors receiving
conventional therapy) [3,4].
Levofloxacin prophylaxis during neutropenia for high
risk patients has been shown to be effective to prevent
all infection related events by a study published in 2005 by
GIMEMA group and confirmed by a Cochrane systematic
review in 2012 [5,6]. However, empirical antifungal ther-
apy and investigation for invasive fungal infections shouldl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of neutropenic episodes according
to clinical or microbiological confirmation of infection
Induction Consolidation p value
(N = 81) (N = 210)
Fever 27 (33,4%) 40 (19,1%) < 0.001
Clinical diagnosis 9 (11,1%) 5 (2,4%) 0.002
Microbiological diagnosis 24 (29,6%) 66 (31,4%) 0.766
Possible IFI 2 (2,5%)
Probable IFI 3 (3,%)
Definite IFI 4 (4,9%) 1 (0,5%) < 0.001
Total 69 112
Patients without fever 12 (14,8%) 98 (46.6%) < 0.001
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fever after 4–7 days of antibiotics and whose duration of
neutropenia is expected to be >7 days [7]. Preemptive anti-
fungal management is acceptable as an alternative to
empirical antifungal therapy in a subset of high-risk
neutropenic patients [8,9].
The primary objective of this study was to report the
incidence of fever and clinically or microbiologically
proven bacterial or fungal infections during neutro-
penic episodes of patients with AML undergoing levo-
floxacin prophylaxis. Our focus was on bloodstream
infections [10].
Methods
This retrospective analysis was conducted in the Depart-
ment of Hematology 2, at San Giovanni Battista Hospital
in Turin between June 2001 and December 2007. The
Ethics Committee approval was unnecessary due to the
retrospective nature of the study and was waived with
the approval of the Hospital Medical Direction for pa-
tients given prophylaxis with levofloxacin before 2006.
Beginning in 2006, consecutive adult patients with AML
were prospectively included in the multicenter AML 02/
06 (EudraCT number 2006-003817-429) study by our
center, belonging to the Northern Italy Leukaemia
Group (NILG) and approved by the Ethical Committee.
All included patients were treated with standard induc-
tion chemotherapy ICE followed by post-remissional
therapy with repeated consolidation courses with high
dose cytarabine (HDAraC) plus peripheral progenitor cell
support [11]. Each patient signed an informed consent to
be included in the study and to receive chemotherapy,
antinfective and nutritional therapy. As prescribed in the
protocol, all patients received antibiotic prophylaxis with
oral levofloxacin at 500 mg/die, given during the induction
phase from the day of hospitalization until the recovery of
blood neutrophils count over 1000/μl, after chemotherapy.
In the following courses of chemotherapy levofloxacin at
the same dosage was administered from first day after the
end of chemotherapy until the recovery of blood neutro-
phils count over 1000/μl. Antifungal prophylaxis was
administered to all patients with oral itraconazole 200 mg
twice a day.
In patients with neutropenia (≤ 500/mm3) and fever
(defined as external temperature ≥ 38°C) the following
baseline diagnostic investigations were performed: chest
X-rays, blood cultures, sputum and urine cultures, serum
galactomannan antigen, Streptococcus pneumoniae and
Legionella spp. urinary antigens. Empiric treatment, based
on international recommendation at the time, could vary
among the centres, according to local epidemiology.
Neutropenic febrile patients were treated with empirical
antibiotic therapy with piperacillin-tazobactam or merope-
nem. Vancomycin and/or amikacin were added if feverwas deemed to be complicated, such as suggestion of
intravascular catheter-related infection, MRSA coloni-
zation, hypotension and/or organ failure.
Data collected included demographics, presence and
characteristics of central venous catheter (type, site, in-
sertion and removal), duration of antibiotic prophylaxis
received, description of febrile episodes (duration, initial
neutrophil count, blood pressure, SO2%, respiratory rate,
body temperature), type and length of antibiotics, results
of investigations (chest X-ray and CT scan, ultrasounds,
brain CT scan) and microbiology tests (site of infection,
analyzed material, isolation of microorganism).
Data was entered into an electronic database and ana-
lyzed with Microsoft Excel. Statistical analysis was per-
formed with STATA 11 program (Stata Corporation,
USA). Chi-square test was used for categorical variables.
Continuous variables were compared by Student’s t-test
if normally distributed and the Mann–Whitney U-test
if non-normally distributed. All p values were two sided,
p value of <0.05 was considered significant. Values for
continuous and categorical variables are expressed as the
mean ± SD and median (IQR) or percentage of the
group from which they are derived, respectively.
Results
A total of 81 patients with diagnosis of AML were
observed during the study period (46 males and 35
females). The median age was 49.7 ± 11.4 years (range
23–69 years). There were 291 neutropenic episodes, 81
(27,8%) during in the induction and 210 (72,2%) during
the consolidation phase; fever was recorded in 181 epi-
sodes, 69 during induction (85.2%) and 112 (53.4%) during
consolidation cycles. Of the latter 112 episodes 32 (28,6%)
were during the second cycle; 25 (22,3%), 27 (24,1%), 17
(15,2%) and 11 (9,8%) during the third, fourth, fifth and
sixth consolidation cycle, respectively. The characteristics
are reported in Table 1. The mean duration of neutropenia
was 14 (range 13–19) days for the induction phase (ICE),
7 (range 5–11) and 5 (range 4–7) days for the second and
Table 2 Etiology of positive blood cultures during the
induction and consolidation phase
Gram-positives Gram-negatives
(N = 33) (N = 46)
Induction (N = 81) S. epidermidis (11) E. cloacae (2)
Neutropenic fever
episodes = 69
E. faecium (3) E. coli (1)
S. mitis (1) K. pneumoniae (1)
Corynebacterium spp. (1)
Total (N = 20) 16 4
Consolidation (N = 210) S. epidermidis (8) E. coli (32)
Neutropenic fever
episodes = 112
MRSA (3) P. aeruginosa (3)
S. hominis (3) E. cloacae (2)
Corynebacterium spp (2) S. maltophilia (2)
E. faecalis (1) S. marcescens (1)
Citrobacter (1)
K. pneumoniae (1)
Total (N = 59) 17 42
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duration of neutropenia following the peripheral stem cells
transplantation was 12 days. The median number of days
of fever was significantly higher in the induction phase
than in the consolidation chemotherapy (9 vs 4 days,
p < 0.001).
All the patients carried a Hohn central venous catheter
both in induction and in consolidation phase. Twenty-
four patients underwent allogenic transplantation (29,6%).
In twenty-six patients (32,1%) high-dose of citarabine
was followed by peripheral stem cells transplantation
(preceded by rescue of peripheral blood progenitor cells).
Pneumonia (fungi included) was the most common
clinical manifestation: during the induction chemo-
therapy in 69 patients with fever (19 cases, 27,5%) and
during the consolidation chemotherapy in 112 febrile
neutropenia episodes (12 cases, 10,7%).
Piperacillin/tazobactam was mainly administered as
empirical treatment, followed by meropenem or ceftazi-
dime in association with amikacin; vancomycin was
empirically added in 21, 11 and 4 cases, respectively.
Resolution of fever during induction chemotherapy was
observed in 47,6% of patients treated with piperacillin/
tazobactam, in 42,9% with ceftazidime and amikacin and
40% with meropenem. A higher rate of clinical success
(disappearance of fever or resolution of clinical manifest-
ation) was reported during the consolidation phase in
91,7% of patients treated with meropenem, 88,9% treated
with meropenem and glicopeptide, 75% treated with
ceftriaxone and in 68,7% of those who received ceftazi-
dime and amikacin. The lower duration of neutropenia
during the consolidation probably explained the higher
rate of fever disappearance in the consolidation phase
compared with the induction phase (79.5% versus
52.2%, p = 0.00018).
Amongst the febrile neutropenic episodes, 29% were
associated with bacteraemia during the induction (20
positive blood cultures for bacteria over 69 febrile neu-
tropenic episodes) and 51% during the consolidation
phase (59 positive blood cultures for bacteria over 112
febrile neutropenic episodes).
Amongst bloodstream isolates, all coagulase-negative
Staphylococci were methicillin-resistant and resistant to
fluoroquinolones. Enterococcus faecalis isolates were re-
sistant to ampicillin but sensitive to vancomycin and
teicoplanin. Amongst Enterococcus faecium, vancomycin
and teicoplanin were active in vitro against two out of
three isolates (66,6%). The resistance to fluoroquino-
lones was also complete amongst the strains of Coryne-
bacterium spp and it was 78% in Escherichia coli, which
were ESBL producers in 12.1% of cases (N = 4), all in
the consolidation phases.
The main finding of this study was that bloodstream
isolates were predominantly represented by Gram-positives, 80% vs 27,6% (16 cases out of 20 vs 17
cases out of 59) or by Gram-negatives, 20% vs 72,4%
(4 cases out of 20 vs 42 cases out of 59) during
the induction or consolidation phases, respectively
(p < 0.001) (Table 2).
There were ten cases of fungal infections, all but one
during the induction phase (2 possible, 3 probable and 5
proven). Proven invasive pulmonary aspergillosis were
diagnosed in four cases.
During the study six patients died (7,4%): four with in-
vasive fungal disease, one with Legionella pneumonia
and refractory disease and one with refractory disease
without signs of infection.Discussion
Levofloxacin prophylaxis of febrile episodes in neu-
tropenic patients has been shown to be effective by
the GIMEMA study in 2005 [5]. In the same paper
the authors also emphasized the need for surveil-
lance for the possible development of antibiotic re-
sistance. In the following years both IDSA guidelines
[3] and a Cochrane review of 109 randomized trials
[6] confirmed the utility of levofloxacin prophylaxis
in selected patient populations with oncohaematolo-
gic disease. In this study we retrospectively evaluated
neutropenic episodes in patients with AML who re-
ceived levofloxacin prophylaxis. We found a statisti-
cally significant prevalence of Gram-positive bacteria
during induction chemotherapy and Gram-negatives
during consolidation phase.
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of chemotherapy may have a role in selection of isolated
strains, as suggested by Bucaneve et al. in their seminal
paper. A recent systematic review of RCTs and quasi-
RCTs by Cochrane in 2012 demonstrated that levofloxa-
cin prophylaxis significantly reduced all-cause mortality
and infection-related mortality, compared to placebo
and also significantly reduced febrile episodes [6]. Ac-
cording to those results, quinolone prophylaxis did not
increase the incidence of Gram-positive bacteraemia
and, more importantly, there was no significant differ-
ences in the number of patients developing infections
caused by organisms resistant to quinolones.
The spectrum of coverage of fluoroquinolones may
account for a lower incidence of bacteraemia by Gram-
negatives in the induction phase observed in our study,
where the isolation of Gram-positive bacteria may be
explained by partial efficacy of the prophylaxis regimen,
excluding multidrug resistant strains. The significantly
higher prevalence of Gram-negatives during the consoli-
dation phase may be explained by the previous adminis-
tration of levofloxacin prophylaxis, since as many as 73,7%
of Gram-negatives were resistant to fluoroquinolones
(78.9% of E. coli were resistant to ciprofloxacin), corre-
sponding to 59,6% of the total number of Gram-positives
and Gram-negatives. In the induction phase Gram-
negatives bacteria resistant to fluoroquinolones accounted
for only 15,4% of the total number of bacteria.
Of course we cannot exclude that differences in eti-
ology could be due to other factors, such as comorbidi-
ties and hospital stay. However, during the study period
there was a lower rate of fluoroquinolones resistance
amongst bloodstream E. coli hospital isolates (29-38%)
and there were few cases of bloodstream infections
caused by ESBL-producers E. coli, with resistance to
fluoroquinolones in 76.3% of strains [12]. Amongst
patients undergoing allogenic transplant and levofloxa-
cin prophylaxis, coagulase-negative staphylococci were
the most commonly isolated Gram-positive pathogens
and E. coli was the most commonly isolated Gram-
negative bacteria [13]. Resistance to fluoroquinolones
was 87% amongst Gram-positive isolates and 50%
amongst Gram-negative rods. The issue of growing rate
of fluoroquinolone resistance and ESBL production by
Gram-negatives may require special attention even at
hospital admission in selected patient population where
a clinical risk score may be useful [14].
However, since fever disappeared more rapidly during
the consolidation phases of chemotherapy, because of
reduced duration of neutropenia together with the prob-
able effect of empiric antibiotic treatment, the adminis-
tration of levofloxacin prophylaxis might be discussed
under the view of the local epidemiology, especially
when multiple or prolonged administration is expected.Conclusions
Fluoroquinolone prophylaxis is frequently used world-
wide in high-risk neutropenic patients. However, few
reports have studied the rate of resistance amongst
Gram-positive and Gram-negative bloodstream isolates
during induction and consolidation phases. In our study
the rate and resistance of Gram-negatives was signifi-
cantly higher during the consolidation phase, where the
duration of neutropenia is lower and the resolution of
fever after empiric antibiotic treatment is higher. If these
data will be confirmed, levofloxacin prophylaxis might
be at least less extensively administered during the
consolidation chemotherapy. Constant monitoring for
fluoroquinolone resistance amongst Gram-negative bac-
teria is required to preserve the efficacy of levofloxacin
prophylaxis.
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